Bioharvest Sciences Inc 8MV0.MU is expected to report resultson August 11 for the period ending June 30 2025
The Vancouver British Columbia-based company is expected to report revenue of $8.533 million, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Bioharvest Sciences Inc is for a loss of 11 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Bioharvest Sciences Inc is $14.50, about 44.1% above its last closing price of $8.10
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.13 | -0.12 | -0.13 | Missed | -8.3 |
Dec. 31 2025 | -0.12 | -0.12 | -0.17 | Missed | -37.8 |
| |||||
| |||||
|
This summary was machine generated August 8 at 15:16 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)